NCPC(SH:600812)2022-04-27 16:00Financial Performance - The company's operating revenue for 2021 was approximately ¥10.38 billion, a decrease of 9.64% compared to ¥11.49 billion in 2020[27]. - The net profit attributable to shareholders was ¥18.73 million, down 80.76% from ¥97.32 million in the previous year[27]. - The total assets at the end of 2021 were approximately ¥24.93 billion, reflecting a 4.17% increase from ¥23.93 billion in 2020[27]. - The basic earnings per share for 2021 were ¥0.011, a decline of 81.67% from ¥0.060 in 2020[28]. - The weighted average return on net assets was 0.31%, down from 1.70% in 2020, indicating a decrease of 1.39 percentage points[28]. - The company reported a net loss of ¥49.20 million after deducting non-recurring gains and losses, compared to a loss of ¥61.91 million in 2020[27]. - The first quarter of 2021 saw an operating revenue of approximately ¥2.71 billion, with a net loss of ¥57.20 million attributable to shareholders[30]. - The company achieved a total revenue of 3.29 billion yuan, with export revenue reaching 1.7 billion yuan[52]. - Total revenue for the reporting period reached approximately CNY 10.30 billion, reflecting a decrease of 9.85% year-over-year[115]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 0.6 per 10 shares, totaling RMB 102,943,822.2, which represents 549.69% of the net profit attributable to shareholders for the year[6]. - As of December 31, 2021, the company has retained undistributed profits amounting to RMB 714,464,297.92[6]. - The company has no plans for capital reserve conversion into share capital for this period[6]. Audit and Compliance - The company has received a standard unqualified audit opinion from Zhongtian Yun Accounting Firm for its 2021 financial statements[5]. - The company’s financial report has been confirmed as true, accurate, and complete by its board of directors and senior management[4]. - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for providing guarantees[8]. Research and Development - The company applied for 41 patents, including 25 invention patents, and was recognized as a "growing new R&D institution" in Hebei Province[36]. - The company has established a comprehensive three-tier R&D system, including four national-level and eight provincial-level R&D platforms, enhancing collaboration with prestigious institutions like Tsinghua University[117]. - The company is focusing on the development of new products, with ongoing projects in various stages, including clinical trials and preclinical research[120]. - The R&D investment amounted to 505 million RMB, representing 4.86% of operating revenue, which is in line with the industry average[131]. Market and Product Development - The company is focusing on expanding its market presence in the Asia-Pacific region, aiming for a 15% increase in market share over the next two years[99]. - The company is actively pursuing international market expansion, particularly in high-end markets such as Europe and the United States[155]. - The company is considering potential acquisitions to enhance its product portfolio and strengthen its market position, with a budget of $100 million allocated for this purpose[99]. - The company plans to enhance its core competitiveness by accelerating technological advancements and focusing on the development of monoclonal antibodies and recombinant proteins[155]. Operational Efficiency and Cost Management - The overall operating cost decreased by 9.50% year-over-year, indicating improved cost management[115]. - The company plans to reduce operational costs by 10% through efficiency improvements in the supply chain[177]. - The company is committed to optimizing its resource allocation and organizational support to align with its strategic goals of marketization, capitalization, and internationalization[152]. Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 11,501[199]. - The company implements a performance-based salary system, with a focus on key talents and positions[200]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 10.6479 million yuan[186]. Future Outlook and Strategic Initiatives - Future guidance includes a focus on sustainable practices in production and distribution, aiming to reduce carbon emissions by 25% by 2025[99]. - The company aims to achieve a revenue target of 12 billion yuan in 2022, focusing on market-oriented and capital-driven strategies[153]. - The company is investing in new product development, particularly in the pharmaceutical sector, with a budget allocation of 200 million for R&D[174]. - The company plans to launch two new products in Q2 2022, expected to contribute an additional 5% to overall revenue[174].